Rapport Therapeutics to Present at Key Healthcare Conferences
Rapport Therapeutics, Inc. (Nasdaq: RAPP), a pioneering biotechnology firm based in Boston and San Diego, is set to make significant contributions at two notable investor conferences this November. The company focuses on the development of innovative small molecule precision medicines aimed at addressing central nervous system (CNS) disorders.
Details of the Upcoming Conferences
Management at Rapport Therapeutics will engage in fireside chats at the following conferences:
Stifel Healthcare Conference
This conference will take place in New York City on a designated day, where participants can explore the latest advancements and insights from the field of biotechnology. Rapport's presentation is scheduled for 1:15pm ET.
Jefferies London Healthcare Conference
Soon after the Stifel event, Rapport Therapeutics will be featured at the Jefferies London Healthcare Conference. This discussion is set for 4:00pm GMT/11am ET, providing valuable information on the company's pioneering efforts in CNS therapies.
Company Overview and Innovations
Rapport Therapeutics is dedicated to creating transformative neuromedicines leveraging their proprietary RAP technology platform. Their outstanding work in understanding receptor associated proteins (RAPs) in the brain distinguishes the firm in the biotechnology landscape.
The company's leading clinical program, RAP-219, is specifically designed to target particular RAPs expressed only in select areas of the brain. This approach aims to provide more effective treatments for conditions such as focal epilepsy, peripheral neuropathic pain, and bipolar disorder.
Advancements in Clinical Trials
The clinical trials for RAP-219 are progressing at an exciting pace, with further explorations into appropriate treatments for various CNS disorders, including chronic pain and hearing disorders. These initiatives highlight Rapport's commitment to overcoming challenges in neurological drug discovery.
Connecting with Rapport Therapeutics
For stakeholders and interested individuals, live and archived webcasts of the presentations will be available in the “Investors” section of Rapport Therapeutics’ website. This transparency allows investors and healthcare professionals to remain informed about the company’s developments and strategies.
Contact Information
For further inquiries, the company is led by Julie DiCarlo, the Head of Communications & IR, who is accessible via email for any interests related to investor relations or communications.
Frequently Asked Questions
What is the purpose of the conferences?
The conferences provide a platform for Rapport Therapeutics to share insights about their innovative treatments and future plans in the biotechnology sector.
How does RAP-219 work?
RAP-219 selectively targets receptor associated proteins in specific brain regions to enhance treatment for CNS disorders.
Where can I find more information about Rapport Therapeutics?
You can visit their official website to access resources about their clinical programs and investor relations.
Who can attend the webcasts?
The live and archived webcasts are available to the public, ensuring transparency for all interested parties.
Which CNS disorders does Rapport focus on?
Rapport Therapeutics is focusing on focal epilepsy, peripheral neuropathic pain, bipolar disorder, chronic pain, and hearing disorders.